Nanobiotix S.A. (NASDAQ:NBTX - Get Free Report)'s stock price fell 1.6% during mid-day trading on Tuesday . The company traded as low as $6.10 and last traded at $6.10. 1,640 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 13,602 shares. The stock had previously closed at $6.20.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on NBTX. Leerink Partnrs reissued an "outperform" rating on shares of Nanobiotix in a research report on Friday, December 8th. SVB Leerink began coverage on Nanobiotix in a research report on Friday, December 8th. They set an "outperform" rating and a $11.00 target price on the stock.
Check Out Our Latest Analysis on NBTX
Nanobiotix Trading Up 0.5 %
The company has a 50-day moving average price of $6.81 and a two-hundred day moving average price of $6.81.
Hedge Funds Weigh In On Nanobiotix
An institutional investor recently bought a new position in Nanobiotix stock. Johnson & Johnson acquired a new stake in shares of Nanobiotix S.A. (NASDAQ:NBTX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 959,637 shares of the company's stock, valued at approximately $8,397,000. Nanobiotix accounts for 3.1% of Johnson & Johnson's portfolio, making the stock its 9th biggest holding. Johnson & Johnson owned 2.65% of Nanobiotix as of its most recent SEC filing. Hedge funds and other institutional investors own 38.81% of the company's stock.
Nanobiotix Company Profile
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Recommended Stories
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
